vs
Side-by-side financial comparison of CytoMed Therapeutics Ltd (GDTC) and MEDICINOVA INC (MNOV). Click either name above to swap in a different company.
MEDICINOVA INC is the larger business by last-quarter revenue ($123.3K vs $115.4K, roughly 1.1× CytoMed Therapeutics Ltd). CytoMed Therapeutics Ltd produced more free cash flow last quarter ($-855.4K vs $-1.7M).
CytoMed Therapeutics Ltd is a clinical-stage biopharmaceutical company focused on developing innovative allogeneic chimeric antigen receptor (CAR-T) cell therapies for treating hematological malignancies and solid tumors. It primarily serves global oncology patient populations and advances candidates targeting unmet medical needs in the immuno-oncology segment.
Medicinova Inc. is a clinical-stage biopharmaceutical firm developing novel therapies for unmet medical needs, focusing on immunology, inflammatory disorders and oncology. It operates across North America and Asia, advancing pipeline candidates through clinical trials to serve patients with limited treatment options.
GDTC vs MNOV — Head-to-Head
Income Statement — Q2 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $115.4K | $123.3K |
| Net Profit | — | $-3.1M |
| Gross Margin | — | — |
| Operating Margin | — | -2741.7% |
| Net Margin | — | -2473.6% |
| Revenue YoY | — | — |
| Net Profit YoY | — | -6.9% |
| EPS (diluted) | — | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | — | $123.3K | ||
| Q2 25 | $115.4K | $134.6K |
| Q3 25 | — | $-3.1M | ||
| Q2 25 | — | $-3.3M |
| Q3 25 | — | -2741.7% | ||
| Q2 25 | — | -2679.9% |
| Q3 25 | — | -2473.6% | ||
| Q2 25 | — | -2437.7% |
| Q3 25 | — | $-0.06 | ||
| Q2 25 | — | $-0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $32.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $44.0M |
| Total Assets | — | $47.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $32.6M | ||
| Q2 25 | — | $34.3M |
| Q3 25 | — | $44.0M | ||
| Q2 25 | — | $46.9M |
| Q3 25 | — | $47.6M | ||
| Q2 25 | — | $49.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-855.3K | $-1.7M |
| Free Cash FlowOCF − Capex | $-855.4K | $-1.7M |
| FCF MarginFCF / Revenue | -741.5% | -1383.5% |
| Capex IntensityCapex / Revenue | 0.0% | 2.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $-1.7M | ||
| Q2 25 | $-855.3K | $-2.3M |
| Q3 25 | — | $-1.7M | ||
| Q2 25 | $-855.4K | — |
| Q3 25 | — | -1383.5% | ||
| Q2 25 | -741.5% | — |
| Q3 25 | — | 2.4% | ||
| Q2 25 | 0.0% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
